Idexx Laboratories exceeded earnings expectations for Q4 2024, buoyed by robust performance in its key diagnostic segments.

B, consensus $3.41B. Backs FY25 capital expenditures view $115M. Backs FY25 free cash flow view $350M-$400M. The company said, W ...

Reports Q1 revenue $955M, consensus $997.1M. Sean Keohane, Cabot (CBT) President and Chief Executive Officer commented: “We continued to ...

For each 5 percentage point increase in the U.S. tariff rate, the S&P 500 (SP500) EPS would reduce by 1-2%, said David Kostin, chief U.S. equity strategist at Goldman Sachs, in a note. A sustained 25% ...

Despite a sharp tech sell-off earlier this week sparked by the launch of Chinese startup DeepSeek's AI model, major market ...

Polen Capital, an investment management company, released its “Polen US SMID Company Growth Strategy” fourth-quarter 2024 ...

Looking ahead to 2025, Quest Diagnostics projects revenue in the range of $10.70 billion to $10.85 billion, indicating ...

Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's ...

Danaher's Q4 earnings missed expectations due to a decline in its diagnostics segment, despite stronger sales in ...

Revenue only grew 2 percent year over year for Tesla in Q4 2024.